Climb Bio, Inc.
CLYMHealthcare|Biotechnology|US
$10.29
+1.42 (+16.01%)
DCF Value
$0.49
Tangible Book / Share
$2.85
Cash / Share
$2.57
Financials
Financial Snapshot
Market Cap
$591.0M
Enterprise Value
$552.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$59.3M
Cash & Investments
$205.4M
Net Cash
$204.4M
Free Cash Flow (TTM)
-$53.6M
Operating CF (TTM)
-$52.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$205.4M
Quarterly Burn
$13.1M
Monthly Burn
$4.4M
Est. Runway
~15.6 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $21.2M | $20.5M | $136.5M | $123.6M | $106.8M | $150.9M | $101.1M | $205.4M | |
| Operating Cash Flow | -$5.0M | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.4M | -$52.6M | |
| Free Cash Flow | -$5.0M | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.5M | -$53.6M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$186.0K | -$1.1M | |
| Financing Cash Flow | $26.2M | $4.9M | $177.2M | $0.00 | $841.0K | $130.7M | -$21.0K | $104.9M |
R&D Spending
R&D (TTM)
$43.8M
R&D Intensity
—
R&D Growth vs Prior
-6.0%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $4.0M | $9.3M | $23.3M | $26.2M | $15.4M | $14.3M | $46.6M | $43.8M | |
| SG&A | $677.0K | $2.4M | $12.3M | $18.9M | $24.9M | $16.0M | $21.2M | $22.9M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $97.0K | $68.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$97.0K | -$68.0K | |
| R&D | $4.0M | $9.3M | $23.3M | $26.2M | $15.4M | $14.3M | $46.6M | $43.8M | |
| SG&A | $677.0K | $2.4M | $12.3M | $18.9M | $24.9M | $16.0M | $21.2M | $22.9M | |
| Operating Income | -$7.4M | -$20.9M | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M | -$66.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$6.5M | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M | -$59.3M | |
| Net Income | -$6.5M | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M | -$59.3M | |
| EPS (Diluted) | -0.56 | -1.97 | -4.24 | -1.72 | -1.30 | -1.53 | -0.88 | -0.82 | |
| EBITDA | -$4.7M | -$11.8M | -$47.5M | -$45.2M | -$35.1M | -$30.4M | -$59.8M | -$63.4M | |
| Shares Out. (M) | 11.66 | 11.66 | 12.26 | 26.31 | 26.99 | 48.16 | 67.81 | 80.03 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.2M | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M | $39.7M | |
| Short-Term Investments | $0.00 | $0.00 | $89.6M | $80.0M | $13.7M | $63.7M | $65.4M | $165.7M | |
| Total Current Assets | $21.3M | $22.0M | $148.3M | $134.4M | $110.3M | $154.9M | $105.8M | $210.1M | |
| Total Assets | $21.4M | $24.6M | $173.2M | $135.0M | $110.5M | $217.2M | $167.7M | $236.6M | |
| Total Current Liabilities | $783.0K | $3.1M | $6.0M | $6.1M | $2.8M | $4.9M | $7.0M | $7.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $783.0K | $3.1M | $6.0M | $6.3M | $2.9M | $5.3M | $7.3M | $8.5M | |
| Stockholders' Equity | $20.6M | $21.6M | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M | $228.1M | |
| Retained Earnings | -$7.5M | -$28.1M | -$75.6M | -$120.9M | -$156.0M | -$229.9M | -$289.7M | -$331.5M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.4M | -$52.6M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$186.0K | -$1.1M | |
| Free Cash Flow | -$5.0M | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.5M | -$53.6M | |
| Investing Cash Flow | $0.00 | $8.1M | -$115.0M | $34.4M | $69.0M | -$121.1M | $2.8M | -$38.3M | |
| Financing Cash Flow | $26.2M | $4.9M | $177.2M | $0.00 | $841.0K | $130.7M | -$21.0K | $104.9M | |
| Issuance of Stock | $0.00 | $0.00 | $83.1M | $0.00 | $841.0K | $119.8M | -$21.0K | $105.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $707.0K | $3.7M | $7.0M | $12.8M | $5.6M | $8.1M | $6.2M | |
| Net Change in Cash | $21.2M | -$736.0K | $26.4M | -$3.3M | $49.5M | -$5.9M | -$51.5M | $14.1M |
Dilution Tracker
Shares outstanding grew 481.5% over 5 years — significant dilution
Shares Outstanding
57M
5-Year Share Growth
+481.5%
Stock Issuance (TTM)
$105.2M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 11.66 | 11.66 | 12.26 | 26.31 | 26.99 | 48.16 | 67.81 | 80.03 | |
| Change vs Prior % | — | 0.0% | 5.1% | 114.6% | 2.6% | 78.5% | 40.8% | 18.0% | |
| Stock Issuance | $0.00 | $0.00 | $83.1M | $0.00 | $841.0K | $119.8M | -$21.0K | $105.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $707.0K | $3.7M | $7.0M | $12.8M | $5.6M | $8.1M | $6.2M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -31.8% | -95.8% | -28.4% | -35.2% | -32.6% | -34.9% | -37.3% | -30.6% | |
| ROA % | -30.6% | -83.9% | -27.4% | -33.5% | -31.8% | -34.0% | -35.7% | -25.1% | |
| ROIC % | -36.1% | -97.0% | -21.3% | -34.9% | -37.3% | -38.6% | -42.2% | -29.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -181.0% | -70.5% | -26.5% | 10.8% | -103.6% | 17.2% | |
| Net Income | 0.0% | -215.7% | -129.7% | 4.7% | 22.4% | -110.4% | 19.0% | |
| EPS (Diluted) | 0.0% | -251.8% | -115.2% | 59.4% | 24.4% | -17.7% | 42.5% | |
| Operating Cash Flow | 0.0% | -181.5% | -155.9% | -3.6% | 44.9% | 24.5% | -249.3% | |
| Free Cash Flow | 0.0% | -181.5% | -155.9% | -3.6% | 44.9% | 24.5% | -250.5% | |
| R&D Expense | 0.0% | 132.4% | 149.6% | 12.4% | -41.2% | -7.0% | 225.2% | |
| SG&A Expense | 0.0% | 258.2% | 409.3% | 53.2% | 31.4% | -35.5% | 32.1% | |
| Total Assets | 0.0% | 15.1% | 603.3% | -22.1% | -18.2% | 96.6% | -22.8% | |
| Book Value / Share | 0.0% | 4.6% | 637.4% | -64.1% | -18.5% | 10.3% | -46.2% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -27.3% | 52.4% | 1.7% | |
| Diluted Shares | 0.0% | 0.0% | 5.1% | 114.6% | 2.6% | 78.5% | 40.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B3.61
10Y Low / Med / High0.41 / 1.69 / 4.43
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.49
Tangible Book / Share
$2.85
Net Current Assets / Share
$3.51
Graham Net-Net
$2.46
Cash / Share
$2.57
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -13.98 | -3.97 | -1.85 | -4.55 | -6.02 | -1.18 | -4.55 | -12.55 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 4.43 | 4.23 | 0.57 | 1.60 | 1.96 | 0.41 | 1.69 | 3.61 | |
| EV/EBITDA | -14.93 | -6.02 | -1.03 | -3.60 | -3.38 | 0.00 | -3.95 | -8.71 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
39.84
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $763.6K | $1.1M |
| Net Income | -$59.5M | -$71.7M | -$128.5M |
| EPS | $-0.79 | $-0.99 | $-1.37 |
| # Analysts (EPS) | 11 | 11 | 13 |